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Abstract
Small animal computed tomography (CT) has poor intrinsic soft tissue contrast, limiting evaluation of intra-abdominal
structures. Using standard intravascular-extracellular intravenous contrast (IE-IV) alone is theoretically limited by long
acquisition times of traditional small animal scanners that may result in equilibration. We assessed whether a negative
contrast strategy of enhancing normal tissue surrounding tumor, instead of the tumor itself, can visualize and quantify
intraperitoneal (IP) cancer in a mouse model. Two and a half weeks after IP injection of Hey A8 cells, four groups of
three animals each were administered serial dilutions of IV Fenestra LC (RES-IV), oral Gastroview, and IP Optiray 320.
Another group of three animals was administered IV Optiray 320 (IE-IV), oral Gastroview, and IP Optiray 320 in suc-
cessive combinations. Both groups were imaged by CT. Tumor and organ Hounsfield units were measured, and
visualization was assessed. With increasing contrast amount, the Hounsfield unit of organs generally increased,
whereas that of tumor remained essentially stable. The visualization of abdominal organs and tumor also generally
increasedwith increasing contrast amount. Visualizationof tumor and itsmargins adjacent to liver, spleen, and stomach
was significantly better on administering RES-IV. However, for tumor adjacent to bladder, both IE-IV and RES-IV
were equivalent. In vivo CT-derived tumor weights correlated highly with ex vivo tumor weights (r = 0.96, P < .0001,
n = 15). Thus, CT using negative contrast enhancement strategy allows visualization and quantification of IP tumors.
Such a strategy will also enable anatomic localization of functional signal for combination/molecular imaging.
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Introduction
Of 58 women, 1 will develop ovarian cancer during her lifetime [1].
It is the most common cause of death from gynecologic malignancy,
and overall, the fifth most common cause of cancer death in women
[2]. An estimated 22,430 new cases are expected to have been de-
tected in the United States in 2007, with 15,280 deaths [3]. If di-
agnosed and treated early, when the cancer is confined to the ovary,
the 5-year survival rate is more than 90%. Unfortunately, only 19%
of cases are found at early stage [1]. Instead, most patients present
with intraperitoneal (IP) disease, which forebodes poor prognosis
[4,5]. After treatment, recurrence is common and most frequently
occurs in the peritoneum.
Several small animal models have been developed to better under-
stand ovarian cancer diagnosis and its progression and to evaluate
new therapies. Among these, orthotopic models are preferred to more
closely mimic human conditions. The most clinically relevant site for
modeling orthotopic ovarian cancer is the peritoneal cavity because
the peritoneal cavity is the principal site of disease in metastatic ovar-
ian cancer; in addition, ovarian cancer commonly initially presents as
IP metastasis [6,7]. Ovarian cancer is also one of the most common
cancers to present as IP metastasis [8]. Localizing the primary tumor
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and assessing the extent of disease are critical during disease evaluation.
However, IP tumors, unlike subcutaneous tumors, are not accessible
for direct assessment; therefore, noninvasive imaging is needed.
A number of problems associated with tumor models may be ad-
dressed by imaging. For example, selecting animals with tumors before
beginning experiments will reduce the number of animals needed for
statistical significance and thus prove cost-effective given the expense
of manufacturing therapeutics. In temporal experiments, it is common
to sacrifice a subset of animals at each time point and perform histo-
pathologic evaluation of the specimen. Tumors often have disparate
growth rates, and sacrifice of the animal limits evaluation to a single
time point instead of permitting individual lesions to be followed longi-
tudinally [9]. Thus, serial imaging is needed to follow the natural his-
tory of disease and to assess therapeutic efficacy.
Clinically, computed tomography (CT) is most commonly used
for staging ovarian cancer. However, unenhanced CT has the draw-
back of poor soft tissue contrast, which results in poor differentia-
tion of tumor from the surrounding organs [10,11]. Commonly in
patients, soft tissue resolution is improved by administering a bolus
intravascular-extracellular intravenous contrast (IE-IV) agent, followed
by rapid CTacquisition. This strategy is used in patients because scan-
ning can be performed within seconds, allowing one to select when to
image the contrast bolus. However, if the acquisition time is long, IV
contrast equilibrates among tissues, resulting in a loss of tissue contrast.
Traditionally, small animal CT is plagued by long acquisition times in
the order of 15 to 20 minutes, thus alternative strategies are required.
An important advantage of CT is that it can be used to perform
fusion imaging with functional imaging methods such as positron
emission tomography (PET) and single photon emission computed
tomography (SPECT). Hybrid machines using dual modalities with
CT are available for small animals, which theoretically allow localiza-
tion of functional signal [12]. However, this requires better visualiza-
tion of individual organs and tumor in the abdomen and pelvis.
We used a negative contrast strategy to enhance normal tissue sur-
rounding the tumor, instead of the more conventional approach of
enhancing the tumor in particular. Normal tissues were enhanced by
using various contrast agents and delivery routes, for example, oral
contrast to enhance the stomach and the bowel, IP contrast to enhance
the peritoneal space and outline the intra-abdominal structures, and
intravenously delivered reticuloendothelial system–specific contrast
(RES-IV) to enhance the liver and spleen. The purpose of our study
was to assess whether a negative contrast strategy can be used to visu-
alize and quantify IP tumor in a mouse model of ovarian cancer.
Materials and Methods
Cell Line and Culture
Ovarian cancer cells, Hey A8 (a kind gift from Dr. Gordon. B.
Mills, Department of Systems Biology, The University of Texas MD
Anderson Cancer Center, Houston, TX), were cultured in RPMI
1640 supplemented with 10% fetal bovine serum, 2 mM L-glutamine,
1× streptomycin-penicillin (Gibco BRL, Carlsbad, CA) at 37°C with
5% CO2.
Animal Experiments
All animal experiments were approved by the Institutional Animal
Care and Use committee. For IP injection, tumor cells were trypsinized,
centrifuged at 1000 rpm × 7 minutes at 4°C, washed twice, and re-
suspended in serum free Hank’s buffered salt solution (HBSS, Life
Technologies, Rockville, MD) at a concentration of 2.5 × 106 cells/ml.
Initially, IP tumors were established in nine nude mice. On the basis
of a power calculation, 2.5 weeks later, the animals were randomly di-
vided into groups of three animals each. At first, three mice were im-
aged by CTwithout any contrast agent (pre-mice). The animals were
then given diatrizoate meglumine and diatrizoate sodium (Gastroview;
Mallinckrodt, Inc, St. Louis, MO) at 45.8, 91.6, or 367 mg/ml (1:8
dilution, 1:4 dilution, or undiluted, respectively) ad libitum overnight.
In the morning, these animals were administered 50, 150, or 300 μl of
glyceryl 2-oleoyl 1, 3-bis [7-(3-amino-2, 4, 6-triiodophenyl)] alkanoate
(Fenestra LC; Advanced Research Technologies, Inc, Montreal, Quebec,
Canada) by tail vein injection (RES-IV, reticuloendothelial system–
specific contrast). After 2 hours, 500 μl of oral diatrizoate meglumine
and diatrizoate sodium was given by gavage at the same concentra-
tions as overnight. Simultaneously, 400 μl of ioversol (Optiray 320;
Mallinckrodt, Inc) was given IP in doses of 40, 80, or 320 mg/ml
(1:8 dilution, 1:4 dilution, or undiluted, respectively). Thereafter, all
animals were scanned by CTafter 45 minutes to 1 hour. Data were used
for Hounsfield unit (HU) measurement and radiologists’ evaluation.
To test intravascular-extracellular IV contrast, based on a power
calculation, another three animals with IP tumors were administered
300 μl of Optiray 320 (IE-IV) at 320 mg/ml by tail vein injection,
and then imaged by CT immediately (capitalizing on the rapid 2-
minute acquisition protocol; see Computed Tomography Protocol)
as well as after a delay of 15 minutes (to evaluate the slower acquisi-
tion time of most small animal CT scanners). On the second day, oral
Gastroview (367 mg/dl) was provided ad libitum overnight, followed
by gavage with 500 μl at the same concentration in the morning. About
45 minutes to 1 hour later, they were administered 300 μl of IE-IV
contrast at 320 mg/ml by tail vein injection, followed by immediate
and delayed acquisition after 15 minutes. On the third day, the animals
were given oral Gastroview (367 mg/dl) ad libitum overnight, followed
by gavage with 500 μl at the same concentration in the morning. They
were also administered 400 μl of IP Optiray 320 at 320 mg/ml. About
45 minutes to 1 hour later, they were administered 300 μl of IE-IV
contrast at 320 mg/ml by tail vein injection, followed by immediate
and delayed acquisition after 15 minutes. Data were used for HUmea-
surement and radiologists’ evaluation.
In another experiment, based on a power calculation, 15 animals were
administered “standardized” doses of contrast: Gastroview (91.6mg/ml)
was provided ad libitum overnight. In the morning, the animals were
administered 300 μl of RES-IV contrast by tail vein injection, followed
2 hours later by gavage with 500 μl of oral Gastroview at the same con-
centration as overnight and 400 μl of IP Optiray 320 at 320 mg/ml.
About 45minutes to 1 hour later, the animals were imaged byCT. From
the CT images, tumor weight was calculated.
For all experiments, after imaging, animals were euthanized, digi-
tally photographed, and the tumors excised and weighed.
Computed Tomography Protocol
The animals were imaged prone using an xSPECT-CT scanner
(Gamma Medica, Flex XO xSPECT). High-resolution CT images
were obtained at 75 kV and 310 μA current at a scanning time of
2minutes per animal. The images have an isotropic voxel size of 170 μm
at 250 milliseconds per frame for a total of 512 images per animal.
AMIRA 3.1 was used to view and normalize the images, from which
HUs were calculated using Image Segmentation editor. To control for
potential partial voluming artifacts, the object of interest was seen in at
least three contiguous slices, and the middle slice was used to assess HU.
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Tumor Weight Measurement
Calculation of tumor weights was performed using ImageJ software,
(http://rsb.info.nih.gov/ij, version 1.38) after converting the images
into DICOM format. For assessing tumor volume, the periphery of
the mass was manually traced on coronal images using a region of in-
terest, and the area of the enclosed region was calculated. The area was
then multiplied by the slice thickness to obtain the volume of the ob-
ject of interest within a slice. To avoid overestimation of tumor size,
one-half of the volume from the most dorsal and most ventral images
containing tumor were used in the volume analysis. Assuming a tumor
density of 1 g/ml, tumor volumes (mm3) were converted to weight (g)
for analysis. These were carried out by two individuals separately and
at different times.
Radiologist Interpretation of Images
The images were arranged randomly, and blinded interpretation
was done by two Board-certified radiologists individually and at dif-
ferent times, for tumor visualization, tumor margin delineation, and
visualization of abdominal organs, including bladder, kidney, bowel,
stomach, liver, spleen, and peritoneal cavity. The images were graded
on a scale of 1 to 5 with 1 = not seen, 2 = poor, 3 = fair, 4 = good, and
5 = excellent. Images of all animals given serial dilutions of contrast,
IE-IV contrast, and standardized doses of contrast were evaluated.
Statistics
Computed tomographic image HU measurements as well as organ/
tumor HU ratios were log-transformed before analysis. A linear mixed
model was used to assess the effect of contrast agents on HUmeasure-
ments and HU ratios. The Wilcoxon rank sum test was used to com-
pare image quality ratings across contrast groups. The Spearman’s
correlation test was used to correlate CT-derived in vivo tumor weight
with ex vivo tumor weight. Bland-Altman analysis was performed.
All tests were two-sided, and P values of 0.05 or lower were consid-
ered statistically significant. Statistical analysis was carried out using
SAS version 9 (SAS Institute, Cary, NC) and S-Plus 7 (Insightful, Inc,
Seattle, WA).
Results
Representative Images
Representative coronal in vivo CT images of mice bearing IP Hey A8
tumor given different doses of oral contrast, IP contrast, and RES-IV
contrast are shown in Figure 1A. In the pre-mice (without any contrast
agent), it was difficult to delineate the tumor because of poor soft tissue
contrast. In addition, there was poor differentiation among almost all
organs such as liver, stomach, spleen, bowel, and bladder. In general, as
the concentration of oral Gastroview, IP Optiray 320, and RES-IV con-
trasts increased, the tumor was better visualized, and the margins were
better delineated from the surrounding organs.
Figure 1B shows immediate and delayed acquisition in vivo CT
images of mice bearing IP Hey A8 tumor after administration of
IE-IV, oral, and IP contrasts. The tumor adjacent to the bladder was
well visualized, and its margins were well delineated in both the imme-
diate and delayed acquisition images. However, the tumor and its
margins adjacent to the liver, spleen, and stomach were not as well seen
on either the immediate or the delayed imaging.
Organ/Tumor Enhancement
The dose dependency of contrast enhancement in the different or-
gans was assessed by HU measurements (Figure 2A). With increas-
ing doses of oral Gastroview, the HU of stomach and bowel increased
significantly. The HU of bowel plateaued at the lowest dose of oral
Gastroview (45.8 mg/ml), whereas the HU of stomach further in-
creased with increasing doses of oral Gastroview. Administration of
RES-IV contrast resulted in a significant increase in the HU of the
liver and spleen. With increasing doses of IP Optiray 320, peritoneal
HU increased; this was also found in the renal cortex and renal pelvis.
The HU of the bladder plateaued at the lowest dose of IP Optiray 320,
40 mg/ml, consistent with concentrated material in urine. In contrast,
the HU of tumor increased only slightly. Mineralized bone was used as
a control because none of the contrast strategies were targeted to min-
eralized bone. As expected, cortical bone did not show any significant
difference in enhancement regardless of contrast administration. Thus,
upon administering increasing doses of contrasts, there was generally
an increase in enhancement of all abdominal organs. In comparison,
tumor HU increase was minimal.
Upon administering IE-IV contrast, along with oral Gastroview and
IP Optiray 320 in successive combinations (Figure 2B), similar results
were obtained. The HU of stomach and bowel increased significantly
upon administering oral Gastroview alongwith IE-IV contrast. TheHU
of the peritoneum increased significantly upon administering IE-IV
contrast; but HU markedly increased upon addition of IP Optiray
320. Further, the 15-minute delayed imaging resulted in greater peri-
toneal HU compared with immediate imaging. The HU of liver, renal
cortex, and renal pelvis increased significantly upon administering
IE-IV contrast alone and with coadministration of IP Optiray 320.
In contrast, the HU of tumor increased slightly. The HU of control
cortical bone did not show any significant difference in enhancement,
as expected.
Tumor Enhancement Compared with Organ Enhancement
Tumor HU in relation to that of surrounding organs at different
doses of contrast is compared in Figure 3, A and B. In the pre-mice,
without any contrast administered, the HU of the tumor was not
significantly different from surrounding organs, except bladder,
where there is a minimal difference, and an expected large difference
compared with bone. As seen in Figure 3A, upon administering oral
Gastroview, IP Optiray 320, and RES-IV contrasts in increasing doses,
the HU of abdominal and pelvic organs increased significantly relative
to that of tumor, and this, in general, was magnified by increasing con-
trast dose. The high HU values in the bladder are expected owing to
the IP contrast uptake by the peritoneal lining into the vascular system
and this intravenous contrast being concentrated by the kidneys and
excreted into the urine. In comparison, the HU of bone remained rela-
tively stable. Thus, the HU of abdominal organs showed a statistically
significant increase relative to the tumor, and this was dependent on
the doses of contrasts.
A similar trend was seen on administering IE-IV contrast successively
in combination with oral Gastroview and IP Optiray 320 (Figure 3B).
Addition of contrasts significantly increased the HU of surrounding
abdominal and pelvic organs compared with tumor.
Ratio of Organ to Tumor Enhancement
To further assess tumor to organ distinction, the ratios of HU of
adjacent organs to tumor adjacent to liver, spleen, and stomach were
evaluated. Representative organs targeted by the different contrast
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agents are plotted in Figure 4A. In the pre-mice, the ratios of bowel,
liver, spleen, and peritoneum to tumor adjacent to liver, spleen, and
stomach were close to 1, confirming poor tissue organ distinction. As
the doses of the contrast agents increased, the ratios in general in-
creased as well (i.e., adjacent organs showed greater enhancement than
tumor) suggesting a dose-dependent response. The ratio of bowel to
tumor became statistically significantly different at 45.8 mg/ml of
oral Gastroview, consistent with the difference in HU of bowel at the
same concentration in Figure 2A. The ratio of peritoneum to tumor
increased to the highest doses used. The ratio of spleen to tumor
showed a similar trend. The ratio of liver to tumor became statistically
significantly different at the lowest dose of RES-IV contrast, again con-
sistent with the increase in liver HU seen in Figure 2A. In keeping with
the mild increase in tumor HU, the ratio of bone to tumor decreased
slightly with increasing doses of contrasts. Thus, the ratios of enhance-
ment of adjacent structures like liver, spleen, bowel, and peritoneum
to tumor adjacent to the liver, spleen, and stomach statistically signifi-
cantly increases and can plateau with increasing doses of contrasts.
Figure 4B compares HU ratios of selected organs to tumor adja-
cent to the liver, spleen, and stomach in mice administered oral, IP,
and RES-IV contrasts versus HU ratios after immediate or delayed
imaging of mice administered oral, IP, and IE-IV contrasts. The ratio
of HU of spleen to tumor was significantly higher with the RES-IV
regimen compared with both immediate and delayed imaging with
the IE-IV regimen. The ratio of HU of liver to tumor also showed a
similar trend. The ratio of HU of bowel to tumor and peritoneum to
tumor increased significantly compared with pre-mice upon admin-
istering contrast, but the ratio was not statistically different among
the contrast regimens.
Qualitative Assessment
Qualitative assessment of the visualization of the IP tumor, its mar-
gins, and of surrounding abdominal structures was performed by two
Board-certified radiologists. The tumor and its margins were not seen
in the pre-mice but were excellently seen in the mice given the highest
doses of contrasts or the standardized dose of the RES-IV contrast regi-
men (Figure 5A). Visualization of all organs improved significantly
with contrasts compared with without contrast (Figure 5B).
Stomach and bowel were well to excellently visualized at a dose
of 91.6 mg/ml of oral Gastroview. Adding oral contrast to RES-IV
or IE-IV contrasts permitted fair to good visualization of stomach
and bowel. Peritoneum, bladder, and kidney visualization was fair to
excellent at 80 mg/ml of IP Optiray 320. The visualization of liver and
spleen was fair to good even at the lowest dose of RES-IV contrast.
Figure 1. (A) Representative white light and in vivo CT images of IP Hey A8 tumors before and after administration of different doses
of oral, IP, and RES-IV contrasts. (B) Representative immediate and delayed (15 minutes) in vivo CT images and white light images of
IP Hey A8 tumors in mice administered oral, IP, and IE-IV contrasts. In the pre-mice, without any contrast, tumor and other organs are
not well visualized. Upon administering contrasts, tumor and organs are better visualized. Tumor appears as areas of low attenuation
compared with adjacent structures. ^ indicates peritoneum; B, bladder; Bn, bone; Bo, bowel; L, liver; S, stomach.
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Tumor and the abdominal organs were well to excellently visualized in
the mice administered standardized doses of contrasts. The visualiza-
tion of bladder and kidney was fair to excellent even in mice adminis-
tered IE-IV contrast alone. Visualization of the peritoneum improved
by adding IP Optiray 320 to IE-IV contrast.
As seen in Figure 5C , visualization and margin delineation of tu-
mor adjacent to the liver, spleen, and stomach were significantly bet-
ter upon administering RES-IV contrast with oral Gastroview and
IP Optiray 320 at the standardized dose compared with immedi-
ate or delayed imaging using IE-IV contrast with oral Gastroview
and IP Optiray 320. No difference was seen for tumor adjacent to
the bladder.
Intraperitoneal Tumor Quantification
Next, we evaluated the ability of the negative contrast CT imaging
method to quantify tumor burden. For this part of the study, stan-
dardized doses of 91.6 mg/ml of oral Gastroview, 320 mg/ml of IP
Optiray 320, and 300 μl of RES-IV contrasts were administered. Tu-
mor weights derived from CT images correlated strongly with
weights of excised tumors (r = 0.96, P < .0001, coefficient of the
Figure 2. (A) Quantification of HU in tumors and individual organs after administration of different doses of RES-IV, oral, and IP contrasts.
(B) Quantification of HU in tumors and individual organs after administration of IE-IV, oral, and/or IP contrast combinations. In general,
the HU of organs increased with increasing amounts of contrasts; in comparison, the HU of tumor increased only minimally. *P< .05 of
dose compared with pre-mice with no contrast administered, within the same organ or tumor. (A) +P < .05 of dose compared with
previousdosewithin the sameorganor tumor. (B) +P< .05of dose comparing immediate to delayed imagingwithin the sameorganor tumor.
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x variable = 1.18, n = 15; Figure 6A). Similar results were obtained by
a second independent reader (r = 0.95, P < .0001, coefficient of the x
variable = 1.06, n = 15; data not shown). These findings suggest that
using the negative contrast strategy, IP tumors can be quantified.
The Bland-Altman analysis was performed of the data in Figure 6A
to compare ex vivo tumor weight with in vivo CT-derived tumor
weight. As shown in Figure 6B, the in vivo CT-derived tumor weight
was on average 0.09 g (±2SD: −0.04 to 0.21) smaller than the ex vivo
tumor weight. The correlation is quite high, and the coefficient of the
x variable suggests that a correction factor of 1.18 may be used when
converting in vivo CT-derived tumor weight to ex vivo tumor weight.
Discussion
Computed tomography, in conjunction with the negative contrast
strategy, can visualize and quantify IP tumor. Ovarian cancer most
Figure 3. (A) Comparison of tumor HU to that of surrounding organs before and after administration of different doses of oral, IP, and
RES-IV contrasts. (B) Comparison of tumor HU to that of surrounding organs before and after administration of oral, IP, and IE-IV con-
trasts after the immediate or a 15-minute delayed imaging. In the pre-mice, tumor HU is primarily similar to HU of surrounding organs.
Generally, with increasing amounts of contrasts, tumor HU becomes significantly lower than that of surrounding organs. *P < .05 com-
pared with tumor adjacent to the liver, spleen, and stomach.
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Figure 4. (A) Ratio of surrounding organ HU to HU of tumor adjacent to liver, spleen, and stomach with different doses of contrast. In the
pre-mice, ratios are close to 1 but, in general, increase with increasing doses of contrast. Bone to tumor HU ratio changes minimally. *P <
.05 of ratio compared with the ratio at the previous dose within the same organ to tumor. (B) Comparison of ratios of HU of spleen, liver,
bowel, and peritoneum to tumor adjacent to the liver, spleen, and stomach in mice administered oral, IP, and RES-IV contrasts at the
highest dose, with immediate and delayed imaging of mice administered oral, IP, and IE-IV contrasts. Ratio of HU of spleen to tumor
is significantly higher with the RES-IV regimen compared with both immediate and delayed imaging with the IE-IV regimen. *P < .05
comparing ratio to pre-mice. +P < .05 comparing ratio for RES-IV regimen to IE-IV regimen.
Figure 5. (A and B) Visualization of tumor and organs improves significantly with contrasts. *P< .05 of dose compared with pre-mice without
any contrast. +P< .05 comparing to previous dose within the same organ or tumor. (C) Visualization of tumor and its margins in mice adminis-
tered oral, IP, and RES-IV contrasts undiluted or at the standardized dose compared with immediate and delayed imaging of mice adminis-
tered oral, IP, and IE-IV contrasts. Visualization and margin delineation of tumor adjacent to the liver, spleen, and stomach are significantly
better inmice administered the RES-IV regimen. For tumor near the bladder, no differencewas seen. *P< .05 comparedwith standardized dose.
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commonly presents as IP tumors in patients [4,5]. Intraperitoneal
tumors are not accessible for direct visualization and measurement
by traditional methods, such as calipers, and therefore need imaging
for evaluation of tumor development, progression, and response to
various therapeutic modalities [13,14].
Unenhanced CT has poor soft tissue contrast resolution. In patients,
IE-IV is routinely used to enhance the tumor with rapid CTacquisition
within 1 to 2 minutes of injection. Coakley et al. [8] reported a sen-
sitivity of 85% to 93% in detecting peritoneal metastases in patients
with ovarian cancer using high-speed spiral CT scanners after giving
oral and IE-IV contrast. Administration of IP contrast further increases
sensitivity in detecting peritoneal metastasis from gynecologic malig-
nancies in patients [15,16].
Owing to the slow speed of most traditional small animal scanners,
which leads to equilibration of IE-IV contrast, such an IV contrast
strategy is not applicable in a majority of animal models. This is sup-
ported by the findings of Weber et al. [17] in their study on imaging
murine liver tumor using micro-CT. They concluded that imaging
intra-abdominal tumors was difficult in animal models because of
a lack of soft tissue contrast between organs. The long acquisition
time (approx. 20 minutes) associated with most micro-CT scanners
precluded the use of conventional water-soluble IE-IV agents.
We used a negative contrast strategy to visualize IP tumors in animal
models, which enhances the organs surrounding the tumor rather than
the tumor itself. Because we used a fast scanner, with an acquisition
time of 2 minutes per animal, we also tested an IE-IV contrast imag-
ing strategy, followed by immediate and delayed CT acquisition after
15 minutes.
Administration of IP contrast opacifies the peritoneal cavity, which
can provide visualization of boundaries between organs [18], and we
hypothesized better distinction of the tumor. However, the organs
and tumor may still oppose each other, limiting distinction. Martiniova
et al. [14] reported that unenhanced CT showed a uniform density of
soft tissue structures in animal models and suggested that administra-
tion of Fenestra LC (RES-IV) through the tail vein can enhance normal
liver compared with a tumor within the liver. We reasoned that RES-IV
can be used to visualize the boundaries of the liver and spleen. Bowel,
including stomach, can also mimic tumor. To fill the bowel, oral con-
trast was provided ad libitum overnight. Because oral contrast may
quickly pass from the stomach to the small bowel, we also gave oral
contrast by gavage, 45 minutes to 1 hour before the scan.
Tumors were established by IP injection of human ovarian cancer
cell line Hey A8. In the first set of experiments, before imaging, mice
were administered oral contrast (Gastroview), IP contrast (Optiray 320),
and IV reticuloendothelial system–specific contrast agent (Fenestra
LC, RES-IV). The oral contrast fills the stomach and bowel, allowing
its visualization. The oral contrast does not escape the bowel. Intra-
peritoneal contrast fills the IP cavity and converts the potential space
of the IP cavity into a real space filled with contrast. This outlines the
IP organs and tumor. It enters slowly, but to a small degree into the
Figure 6. (A) Correlation between in vivo CT-derived tumor weights and ex vivo tumor weights (r = 0.96, P < .0001, coefficient of the
x variable = 1.18, n = 15). (B) Bland-Altman Analysis comparing in vivo CT-derived tumor weights and ex vivo tumor weights.
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vascular system through the peritoneal lining, which allows visualiza-
tion of the kidneys because the kidneys concentrate the now intrave-
nous contrast during the process of urine excretion. We noted that
the kidney contrast increased with IPOptiray 320, with or without con-
current RES-IV contrast (data not shown). RES-IV, which is a lipid-
based formulation, enhances RES organs such as the liver and the
spleen. Fat, which is easily identifiable by its low attenuation and known
anatomic distribution, was not enhanced. These three contrast strate-
gies are specifically designed to outline or enhance normal organs that
abut the ovarian tumor. They are also specifically designed not to en-
hance the tumor in the peritoneal cavity because the tumor does not
fit the categories above. The unenhanced tumor on imaging was con-
firmed at resection, and the image-derived tumor weight correlated
highly with excised tumor weight. Bone was used as a control because
it was not targeted by the contrast strategy, and its HU remained stable
regardless of the contrast regimens.
In pre-mice, without any contrast, there was no significant differ-
ence in the HU of tumor compared with that of surrounding organs.
With increasing doses of contrast, a significant increase occurred in
the HU of abdominal organs surrounding the tumor, allowing better
visualization and delineation of tumor. A slight increase in enhance-
ment of the tumor was seen, which we believe is due to the IP Optiray
320 entering the tumor through the vasculature. This was minor and
did not limit tumor conspicuity.
For the IE-IV contrast imaging strategy, mice with IP tumors
were administered IV Optiray 320 (IE-IV), oral Gastroview, and
IP Optiray 320 in successive combinations. The addition of oral con-
trast significantly increased the HU of the stomach and bowel. The
HU of the peritoneum increased upon administering IE-IV contrast,
and this was greater on delayed imaging because of a leak of contrast
into the peritoneal cavity. Adding IP contrast increased peritoneal
HU further. The HU of liver, spleen, renal cortex, and renal pelvis
increased significantly with the administration of IE-IV contrast
alone. The HU of the tumor on administering IE-IV contrast en-
hanced only slightly implying that the tumors are not very vascular.
Hypovascular tumors are appreciated as low attenuation in the liver
after IV contrast in the portovenous phase because the liver takes up
more contrast compared with the tumor. For vascular tumors, IE-IV
contrast may worsen visualization by causing equalization of en-
hancement between tumor and normal viscera.
The ratios of liver, spleen, bowel, and peritoneum to tumor, which
were close to 1 in the pre-mice, increased significantly upon giving
the different contrast agents, thus improving soft tissue discrimina-
tion. This corresponded with the findings of two Board-certified
radiologists in evaluating tumor visualization, tumor margins, and the
visualization of abdominal organs surrounding the tumor. In general,
increasing concentrations of the contrast improved tumor visualization
and tumor margin delineation.
For visualizing individual organs, good to excellent visualization
was achieved for each organ. In general, visualization improved with
increasing dose, but for some, a plateau was reached. In the case of
liver and spleen, visualization was fair to good even at the lowest dose.
This highlights the importance of qualitative assessment of visualiza-
tion and suggests potential cost savings. Further, high contrast concen-
trations have the potential to cause artifacts, such as beam hardening.
The kidneys could be visualized even in the absence of contrast be-
cause of the surrounding perinephric fat; however, the IP contrast im-
proved their visualization. The visualization of the tumor adjacent to
the liver, spleen, and stomach and the delineation of its margins were
excellent in mice administered oral, IP, and RES-IV contrasts at the
standardized dose. This was significantly better than using oral, IP,
and IE-IV contrasts. This improvement is due to better distinction of
tumor from surrounding viscera, liver, and spleen, which are enhanced
by the RES-specific agent. This is further corroborated by the ratios of
HU of spleen to tumor being statistically significantly higher in mice
administered RES-IV contrast compared with mice administered IE-IV
contrast. The ratios of HU of liver to tumor showed a similar trend. For
visualization and margin delineation of tumor adjacent to the bladder,
imaging with IE-IVor RES-IV contrast agents plus oral and IP contrast
was equivalent owing to the absence of any opposing adjacent organs
with similar enhancement in the pelvis.
We also evaluated the ability of the negative contrast CT strategy to
quantify IP tumor burden. Tumor weights measured ex vivo were used
as the criterion standard.We previously showed thatmagnetic resonance
(MR) imaging of IP tumors correlates strongly with ex vivo tumor
weights (r = 0.97, P < .001) [19]. In the present study, we obtained a
similar significant correlation between the tumor weights obtained
by in vivo CT imaging and the tumor weights ex vivo. Bland-Altman
analysis, performed to compare ex vivo tumor weight with in vivo
CT-derived tumor weight, showed that the in vivo CT-derived tumor
weight was on average 0.09 g (±2SD: −0.04 to 0.21) smaller than the
ex vivo tumor weight. The correlation is quite high, and the coefficient
of the x variable suggests that a slight correction factor may be used
when converting in vivo CT-derived tumor weight to ex vivo tumor
weight. The high degree of correlation (r = 0.96, P < .001) enables longi-
tudinal imaging for following the natural history of disease and the
efficacy of therapeutic intervention. Although we used ovarian cancer
as a model, we expect that this technique can be applied to other IP tu-
mor models such as for colon cancer, liver cancer, pancreatic cancer,
and breast cancer.
Owing to its noninvasive nature, CT can be performed in living
mice serially. In terms of radiation dose, the animals were exposed to
approximately 0.2 cGy per CT scanning session using the xSPECT-
CT scanner (personal communication from the manufacturer, Gamma
Medica). The sensitivity of different strains of mice to radiation varies.
Budach et al. [20] reported that the LD50 of radiation for severe
combined immune deficiency mice is 3 Gy compared with 7.8 Gy
for nonimmunosuppressed mice. Sublethal whole body irradiation
results in damage to the bone marrow and hematopoietic stem cells.
In the spleen, this results in the production of colony-forming units
(CFU-S), which have been used as a measure of radiation sensitivity. In
normal mice, CFU-S appear at approximately 6 Gy, whereas in severe
combined immune deficiency mice, CFU-S appear at 3 Gy [21]. The
low radiation dose used in this study implies that multiple sessions of
CT imaging can be performed without significant injury to the animal.
An important advantage of CT is that it can be used to perform
fusion imaging with functional imaging methods such as PET and
SPECT. Fusion imaging allows localization of functional signal.
Hybrid machines using dual modalities with CT are now available
for small animals. However, many of these CTs are plagued by long
acquisition times and have limited visualization of intra-abdominal
organs. In an earlier study demonstrating the antitumor effects of a
vascular disrupting agent in IP ovarian cancer models, we have shown
that combination imaging using MR and PET can be used to demon-
strate effect of therapy not only anatomically but also metabolically;
however, integrated MR/PETor MR/SPECT scanners are not yet gen-
erally available for animal models, necessitating individual imaging
by the different imaging modalities [19]. This limits coregistration of
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images, and it is practically difficult to obtain near-simultaneous imag-
ing. In terms of PET-CT, Tatsumi et al. [22] reported that combined
PET/CT, using a clinical imaging machine, can be used for sequential
noninvasive imaging of liver tumors in rabbits. In another animal study,
we have demonstrated that combining functional and anatomic imag-
ing by small animal machines can also be used for noninvasive quan-
tification of gene expression in tumors, such as fibrosarcomas; for
anatomic imaging, MR was used to obtain high soft tissue contrast
[23]. Thus, combined anatomic and functional imaging using the neg-
ative contrast strategy should prove useful for a variety of applications.
The value of combined anatomic and functional imaging has also
been demonstrated in the clinic. In a prospective clinical study on
the diagnostic value of 18F-FDG-PET/CT for primary ovarian cancer
in patients, Risum et al. [24] reported a sensitivity of 100% in de-
tecting a malignant pelvic tumor and a specificity of 92.5% compared
with pathologic examination. Hauth et al. [25], evaluating 18F-FDG-
PET/CT for detecting ovarian cancer in patients, reported that the
combination of PET with CT, which added functional information
to morphology, enabled a better differentiation of tumor. Further, com-
bined 18F-FDG-PET/CT imaging has been reported to bemore sensitive
for detecting recurrent ovarian cancer in patients than either modality
alone [26–29]. Our triple-contrast strategy should enable localization of
multiple different functional signals that may originate in the abdomen
or pelvis.
Computed tomography using the negative contrast enhancement
strategy can be used for visualization and quantification of IP tumors.
The negative enhancement CT technique enables longitudinal assess-
ment for studying the biology of the disease and response to therapy.
These techniques should enable localization of IP cancers using both
fast and slow CT scanners.
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